| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.9 |